Clin Cosmet Investig Dermatol. 2026 Sep 8;19:630833. doi: 10.2147/CCID.S630833. eCollection 2026.
ABSTRACT
OBJECTIVE: Atopic dermatitis (AD) is a chronic inflammatory skin condition characterized by epidermal barrier disruption and immune dysregulation. Live-MB2 and CX-2 were used in an ex vivo human skin AD-like model, which provides a biologically relevant platform for assessing cosmetic ingredients targeting AD-like features.
METHODS: An AD-like condition was induced in ex vivo human skin explants by repeated tape stripping followed by 2,4-dinitrochlorobenzene stimulation. Skin tissues were treated with Live-MB2 or CX-2 via topical or dermal exposure. Epidermal thickness, IgE, and filaggrin levels were evaluated using hematoxylin and eosin, immunofluorescence, and Enzyme-Linked Immunosorbent Assay analyses.
RESULTS: Topical application of Live-MB2 and CX-2 significantly reduced epidermal thickness compared with AD-induced controls. IgE levels were significantly reduced, while filaggrin expression indicated a marked increase, indicating barrier recovery. No treatment-related tissue damage was observed.
CONCLUSION: Live-MB2 and CX-2 showed favorable effects on inflammatory and barrier-related parameters in an ex vivo human skin AD-like model, supporting their potential application as cosmetic ingredients for sensitive and atopic-prone skin.
PMID:42732409 | PMC:PMC13570615 | DOI:10.2147/CCID.S630833
